Blue Cross, Drexel collaborating on care delivery research

The Independence Blue Cross Center for Health Care Innovation is collaborating with Drexel University on several research projects aimed at improving the delivery of healthcare.

The partnership is focusing on the following:

  • Identifying Independence members at risk for hospitalization and re-hospitalization, as well as identifying members who would benefit from Independence’s chronic disease outreach programs;
  • Applying machine learning techniques to unstructured data, such as notes from members’ interactions with doctors and other health professionals, to predict future health problems or customer service issues;
  • Evaluating health interventions that can reduce the number of avoidable emergency department visits;
  • Improving the detection of fraudulent claims, predicting when fraud is likely to occur and developing strategies to help members protect their medical identity.

“The future of healthcare is dependent upon finding new ways to use technology and information to predict illness and prevent health problems before they develop,” said Independence President and CEO Daniel J. Hilferty. “This exciting, new research initiative, with one of our region’s premier universities, will help us discover and expand ways to improve health outcomes, lower healthcare costs and enrich our members’ healthcare experience.”

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.